MAP2K7 and colorectal carcinoma: The X-MANTM isogenic HCT116 cell lines [HCT116 Parental (PTEN-competent) and HCT116 PTEN-/- (PTEN-loss)] were treated with increasing concentrations of the MEK inhibitor Tram, the PI3K/mTOR double inhibitor Geda, or their combination (Tram+Geda, 1:1 fixed dose-ratio) for 72 h under different culture conditions: serum-free medium (wo FBS), fibroblast-CM (CM HFF), or direct CRC/fibroblast co-culture (co-co), using GFP-tagged immortalized skin fibroblast (HFF).